Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

1(33.3%)

Phase 1

1(33.3%)

Phase 2

1(33.3%)

3Total

Phase 3(1)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT04160468Phase 3Terminated

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

Role: lead

NCT04597242Unknown

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Role: lead

NCT03163446Phase 2Completed

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Role: lead

NCT02439359Phase 1Completed

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

Role: lead

All 4 trials loaded